Moderna Shares Plunge 26% After Melanoma Vaccine Data Leak

Moderna shares plunged after Phase 3 results for the company's personalized melanoma vaccine surfaced ahead of a planned disclosure, as positive efficacy findings failed to prevent a sharp pullback in the stock. Shares fell to an intraday low of $180.80, down 26.45% from the prior close, before rebounding to $202.63 at the end of the session. Moderna closed down 17.57%, with the low 28.95% below its Oct. 21 high of $254.48. Moderna and Merck developed the treatment together.

Source: TokenPost